- **BIOXYTRAN, INC.** has successfully completed its **second randomized double-blind, placebo-controlled clinical trial** for its leading broad-spectrum antiviral drug candidate, **ProLectin-M**.  **[1445815_7a243531fb4e493393633c35a1270097_1]** 
- This trial was designed to confirm previous Phase 2 study results, which showed ProLectin-M achieved **undetectable levels of Polymerase Chain Reaction (PCR) and infection in less than one week** in treated participants.  **[1445815_7a243531fb4e493393633c35a1270097_1]** 
- The data from this completed trial is expected to inform the **CDSCO for a Phase 3 trial design** and will also be submitted to the **FDA**.  **[1445815_7a243531fb4e493393633c35a1270097_1]** 
- **ProLectin-M** is positioned as the **first oral antiviral sugar chemistry drug**.  **[1445815_7a243531fb4e493393633c35a1270097_0]** **[1445815_7a243531fb4e493393633c35a1270097_1]**

BIOXYTRAN (BIXT)